highperformr logo

Curium Pharma's Overview

Total employees1612
HeadquartersParis
Founded2017

Curium is a global leader in nuclear medicine, providing life-saving diagnostic and therapeutic solutions to over 14 million patients annually. With a presence in over 60 countries, Curium is dedicated to advancing the field of nuclear medicine through innovation, reliability, and a patient-first approach. Our portfolio includes a wide range of radiopharmaceuticals used in imaging and treatment for various conditions such as cancer, and cardiac, neurological and infectious diseases.

Where is Curium Pharma's Headquarters?

HQ Function

Serves as the central hub for global strategy, corporate governance, financial oversight, and key decision-making for Curium's worldwide operations in nuclear medicine.

Notable Features:

Located in a prestigious business district in central Paris, likely featuring modern office amenities designed for international collaboration and executive functions. Its prime location offers excellent connectivity and access to a rich business ecosystem.

Work Culture:

The Paris HQ likely fosters a dynamic, international, and results-oriented work culture, emphasizing innovation, collaboration across global teams, and a strong commitment to the company's mission of improving patient health.

HQ Significance:

The Paris headquarters symbolizes Curium's global reach and its position as a leading European-based player in the nuclear medicine industry. Its location in a major European capital facilitates international business, talent acquisition, and stakeholder engagement.

Values Reflected in HQ: The choice of a prominent, accessible, and international location like Paris reflects Curium's values of global leadership, excellence, innovation, and a commitment to being at the forefront of the pharmaceutical industry.

Location:

Curium supports a wide range of global functions including research and development, manufacturing of SPECT, PET, and therapeutic radiopharmaceuticals through multiple production sites, extensive quality control and assurance, global supply chain and logistics management, commercial operations, sales and marketing, and regulatory affairs across more than 60 countries. This integrated network ensures the reliable supply of nuclear medicine to patients worldwide.

Street Address:

12-14 Rond-Point des Champs-Elysées Marcel Dassault

City:

Paris

State/Province:

Île-de-France

Country:

France

Curium Pharma's Global Presence

Maryland Heights, Missouri, USA

Address: 2703 Wagner Pl, Maryland Heights, MO 63043, USA

Crucial for supplying the North American healthcare system with essential nuclear medicine products, managing regional strategy, and fostering innovation in diagnostic and therapeutic applications.

Petten, Netherlands

Address: Westerduinweg 3, 1755 LE Petten, Netherlands

Essential for the European supply chain of medical radioisotopes, ensuring timely delivery of diagnostic products to hospitals and clinics across the region. Plays a vital role in global Mo-99 supply.

Saclay, Île-de-France, France

Address: Bâtiment 547, CEA Saclay, 91191 Gif-sur-Yvette Cedex, France

Contributes to Curium's innovation pipeline and production capacity in Europe, focusing on specialized diagnostic and therapeutic agents and collaborating with leading research institutions.

Buying Intent Signals for Curium Pharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Curium Pharma

As of April 2025, Curium Pharma' leadership includes:

Chaitanya Sarawate - President & CEO
Benoit Woessmer - Chief Financial Officer
Michael Sattam - Chief Commercial Officer
Ed Porter - Chief Operations Officer
Sakir M. GOKOZAN, MD - Chief Medical Officer
Jean-Philippe Larroi - Chief People Officer
Anne-Sophie Pradon - Chief Legal, Ethics & Compliance Officer

Investors of Curium Pharma

Curium Pharma has been backed by several prominent investors over the years, including:

CapVest Partners LLP

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits0

No major C-suite executive hires or exits have been widely reported for Curium Pharma in the strict period of the last 12 months (approx. mid-2023 to mid-2024). The most significant recent top-level change was the CEO transition in early 2023, which falls outside this specific timeframe.

Technology (Tech Stack) used by Curium Pharma

Discover the tools Curium Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Curium Pharma Email Formats and Examples

Curium Pharma primarily utilizes the `first.last@curiumpharma.com` email format for its employees. This is a common pattern in multinational corporations and ensures a professional and consistent communication style. Other less common formats might exist for specific departments or legacy systems but are not widely prevalent.

first.last@curiumpharma.com

Format

jane.doe@curiumpharma.com

Example

90%

Success rate

News and media

Curium Pharma Official Website / PR NewswireApril 23, 2024

Curium Pharma Receives Positive CHMP Opinion for PYLCLARI® (piflufolastat (18F)) for the Detection of PSMA-Positive Lesions in Patients with Prostate Cancer

Curium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending PYLCLARI® (piflufolastat (18F)) for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer. This marks a significant step towards making this advanced diagnostic agent available to patients in Europe....more

Curium Pharma Official Website / PR NewswireFebruary 27, 2024

Curium Pharma Signs Exclusive Agreement with Radioisotope Life Sciences (RLS) for Lutetium-177 PSMA I&T in South Africa

Curium and Radioisotope Life Sciences (RLS) entered an exclusive agreement for the distribution and commercialization of Curium’s investigational therapeutic candidate Lutetium-177 (Lu-177) PSMA I&T in South Africa, upon marketing authorization. This partnership aims to expand access to innovative radiopharmaceutical therapies for prostate cancer patients in the region....more

Curium Pharma Official Website / Business WireNovember 14, 2023

Curium Pharma Presents Positive Phase 3 Data for Lutetium (177Lu) PSMA I&T Investigational Therapy for Metastatic Castration-Resistant Prostate Cancer at ESMO 2023

Curium presented positive results from its Phase 3 ECLIPSE trial for Lutetium (177Lu) PSMA I&T, an investigational targeted radionuclide therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). The data, shared at the European Society for Medical Oncology (ESMO) Congress 2023, demonstrated promising efficacy and a manageable safety profile, highlighting its potential as a future treatment option....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Curium Pharma, are just a search away.